graph Evidence gap map comparisons
alpelisib based treatmentbuparlisib based treatment
alpelisib plus fulvestrant buparlisib plus fulvestrant
la/mBC - HR-positive - 2nd line (L2) 20      
la/mBC - HR positive - L2 - all population 1   
la/mBC - HR positive - L2 - PIK3CA mutant 1   
Comparator:  vs fulvestrant; 
Risk of bias:  low;   some concerns;   high;  NA;